AVXL - AVXL INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Anavex Life Sciences Corporation Investors with Substantial Losses Have Opportunity to Lead Case | Benzinga
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Anavex Life Sciences Corporation (NASDAQ:AVXL) stock between February 1, 2022 and January 1, 2024, inclusive (the "Class Period"), have until May 13, 2024 to seek appointment as lead plaintiff of the Anavex class action lawsuit. Captioned Blum v. Anavex Life Sciences Corporation, No. 24-cv-01910 (S.D.N.Y.), the Anavex class action lawsuit charges Anavex as well as Anavex executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Anavex class action lawsuit, please provide your information here:
https://www.rgrdlaw.com/cases-anavex-life-sciences-corporation-class-action-lawsuit-avxl.html
You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com. Lead plaintiff motions for the Anavex class action lawsuit must be filed with the court no later than May 13, 2024.
CASE ALLEGATIONS: Anavex investigates, manufactures, and markets pharmaceuticals for central nervous system ("CNS") disorders. According to the complaint, Anavex's primary product is blarcamesine and Anavex sponsored the ...